Australia Acute Respiratory Distress Syndrome Market

Australia Acute Respiratory Distress Syndrome Market Insights Forecasts to 2035

• The Australia Acute Respiratory Distress Syndrome Market Size Was Estimated at USD 33.2 Million in 2024
• The Market Size is Expected to Grow at a CAGR of Around 10.04% from 2025 to 2035
• The Australia Acute Respiratory Distress Syndrome Market Size is Expected to Reach USD 95.1 Million by 2035

According to a research report published by Decision Advisors & Consulting, the Australia acute respiratory distress syndrome market size is anticipated to reach USD 95.1 million by 2035, growing at a CAGR of 10.04% from 2025 to 2035. The acute respiratory distress syndrome market in Australia is driven by advances in ECMO and ventilator technologies, growing ICU infrastructure investment, and rising respiratory disease cases associated with an aging population.

Market Overview

The acute respiratory distress syndrome (ARDS) market encompasses all products and services involved with diagnosing, managing, and treating ARDS (a life-threatening condition caused by severe inflammation and fluid build-up inside the lungs). The market for acute respiratory distress syndrome in Australia is experiencing growth due to an increase in the incidence of respiratory diseases, the increase in post-COVID-19 complications, and an increase in intensive care unit (ICU) admissions of older Australians. The Australian government supports ARDS care through expanding ICU capacity and healthcare funding. For example, Australia recorded 2,655 ICU beds across 226 ICUs in 2023, reflecting sustained federal and state investment in critical-care infrastructure. Additionally, post-pandemic health funding packages exceeding AUD 3.2 billion strengthened hospital preparedness, enabling improved access to ventilators, ECMO systems, and advanced respiratory treatment for ARDS patients. Recent efforts to develop and create new ECMO technology in Australian hospitals, along with improvements in the way that healthcare funding is allocated, are being undertaken to enhance the level of emergency care available to the community and to enable hospitals to provide advanced respiratory treatment capabilities.

Report Coverage

This research report categorizes the market for the Australia acute respiratory distress syndrome market based on various segments and regions, and forecasts revenue growth and analyses trends in each submarket. The report analyses the key growth drivers, opportunities, and challenges influencing the Australia acute respiratory distress syndrome market. Recent market developments and competitive strategies, such as expansion, product launch, development, partnership, merger, and acquisition, have been included to draw the competitive landscape in the market. The report strategically identifies and profiles the key market players and analyses their core competencies in each sub-segment of the Australia acute respiratory distress syndrome market.

Driving Factors

The acute respiratory distress syndrome market in Australia is driven by the prevalence of severe respiratory diseases, including pneumonia, sepsis, and complications after COVID, which are responsible for increased admissions to the ICU. ARDS also benefits from increased investment in the infrastructure of critical care facilities (i.e., ventilators and ECMO systems). Advances in technologies such as diagnostic imaging, respiratory monitoring, central venous pressure (CVP) monitoring (for ARDS), and life support have improved the accuracy and effectiveness of treatment. The demand for advanced ARDS treatment is being sustained by both the increased hospitalisation of an ageing population in Australia, as well as rising incidences of chronic lung disease.

Restraining Factors

The acute respiratory distress syndrome market in Australia is mostly constrained by the high cost of treatment, lack of advanced ECMO and ventilator systems in many rural and regional areas, and the large volume of high-intensity resources required for longer stays in the ICU. In addition, complexity around diagnosis and variation in individual patient response to treatment pose further challenges to managing ARDS effectively.

Market Segmentation

The Australia acute respiratory distress syndrome market share is classified into severity type and end user.

• The moderate segment accounted for the largest revenue market share in 2024 and is expected to grow at a significant CAGR during the forecast period. 

The Australia acute respiratory distress syndrome market is segmented by severity type into mild, moderate, and severe. Among these, the moderate segment accounted for the largest revenue market share in 2024 and is expected to grow at a significant CAGR during the forecast period. This is because moderate ARDS accounts for the majority of confirmed clinical cases, necessitating substantial ICU care, mechanical ventilation, and continuous monitoring. Its increased treatment frequency and longer hospital stays contribute much more to overall market revenue than moderate or severe instances.

• The hospitals and intensive care units segment accounted for the largest revenue share in 2024 and is expected to grow at a significant CAGR during the forecast period. 

The Australia acute respiratory distress syndrome market is segmented by end user into hospitals and intensive care units, specialty clinics, and others. Among these, the hospitals and intensive care units segment accounted for the largest revenue share in 2024 and is expected to grow at a significant CAGR during the forecast period. This is because ARDS patients require advanced life-support systems, mechanical ventilation, ECMO therapy, and constant monitoring, all of which are primarily provided in hospital intensive care units. The segment's greatest revenue share is driven by higher admission volumes, increased treatment complexity, and extensive critical-care infrastructure.

Competitive Analysis:

The report offers the appropriate analysis of the key organizations/companies involved within the Australia acute respiratory distress syndrome market, along with a comparative evaluation primarily based on their product offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborate analysis focusing on the current news and developments of the companies, which includes product development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.

List of Key Companies

• ResMed Inc.      
• EBOS Group
• 4DMedical
• Medical Developments International (MDI)
• Others

Key Target Audience

• Market Players
• Investors
• End-users
• Government Authorities 
• Consulting and Research Firm
• Venture capitalists
• Value-Added Resellers (VARs)

Recent Developments:

• In May 2025, a high-tech life-support machine (ECMO) was highlighted in the media, showing continued reliance on modern ECMO therapy for severe respiratory failure cases in Australian hospitals.
• In October 2024, the Latest data release shows there are 226 ICUs across Australia, reflecting the country’s ramped-up critical-care capacity.

Market Segment

This study forecasts revenue at the Australia, regional, and country levels from 2020 to 2035. Decision Advisors has segmented the Australia acute respiratory distress syndrome market based on the below-mentioned segments:

Australia Acute Respiratory Distress Syndrome Market, By Severity Type

• Mild
• Moderate
• Severe

Australia Acute Respiratory Distress Syndrome Market, By End User

• Hospitals and Intensive Care Units
• Specialty Clinics
• Others

FAQ’s

Q: What is the Australia acute respiratory distress syndrome market size?

A: Australia acute respiratory distress syndrome market size is expected to grow from USD 33.2 million in 2024 to USD 95.1 million by 2035, growing at a CAGR of 10.04% during the forecast period 2025-2035. 

Q: What are the key growth drivers of the market?

A: Market growth is driven by the prevalence of severe respiratory diseases, including pneumonia, sepsis, and complications after COVID, which are responsible for increased admissions to the ICU. ARDS also benefits from increased investment in the infrastructure of critical care facilities (i.e., ventilators and ECMO systems). Advances in technologies such as diagnostic imaging, respiratory monitoring, central venous pressure (CVP) monitoring (for ARDS), and life support have improved the accuracy and effectiveness of treatment.

Q: What factors restrain the Australia acute respiratory distress syndrome market?

A: Constraints include the high cost of treatment, lack of advanced ECMO and ventilator systems in many rural and regional areas, and the large volume of high-intensity resources required for longer stays in the ICU.

Q: How is the market segmented by severity type?

A: The market is segmented into mild, moderate, and severe.

Q: Who are the key players in the Australia acute respiratory distress syndrome market?

A: Key companies include ResMed Inc., EBOS Group, 4DMedical, Medical Developments International (MDI), and Others.

Q: Who are the target audiences for this market report?

A: The report targets market players, investors, end-users, government authorities, consulting and research firms, venture capitalists, and value-added resellers (VARs).